The QualityStocks Daily Tuesday, May 15th, 2018

Today's Top 3 Investment Newsletters

MarketBeat (TXHD) +100.00%

StockMarketWatch (CLWT) +41.51%

QualityStocks (MPIR) +40.00%

The QualityStocks Daily Stock List

Astro Aerospace Ltd. (ASDN)

Penny Stock Hub, Stockwolf, The Street, Stockhouse, 4-Traders, MarketWatch, Business Wire, Simply Wall St, OTC Markets, Stockwatch, and InvestorsHangout reported on Astro Aerospace Ltd. (ASDN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Astro Aerospace Ltd. is the developer of the world’s most advanced autonomous, unmanned, and manned flying vehicles. The Company works to be at the vanguard of this disruptive aerial industry. Astro Aerospace explores ways to apply its technology to worldwide challenges. These challenges include traffic congestion, pollution, and the overall stresses of daily life.

Astro Aerospace has its head office in Lewisville, Texas. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Astro Aerospace’s drones do away with the requirement for gearboxes, water-cooling systems or aerodynamic steering flaps. The drones are outfitted with fiber optic technology. The Company also features its custom-designed Touch Flight Control.

Astro’s in-house developed adaptive flight control algorithm keeps the ASTRO drone stable in most weather conditions, with minimal vibration. ASTRO Drones are a little larger than a compact car. They can fit into most garages.

ASTRO was purposely designed with wide cabin glass for optimal comfort and a 360°surround view. The vehicle has a full carbon body. The vehicle is equipped with 16 individual rotors.

The ASTRO is suitable for operating in densely populated urban environments and it is an environmentally friendly solution. The design of its high-performance electric motor is to run quietly, fluidly, and also totally emission-free.

The ASTRO features Fiber Optic Internal Communications; Touch Flight Control; Adaptive Flight Control Software; and Encrypted Communication Channels. In addition, it features Field Oriented Motor Control; Fly-by-wire joystick; LTE (4G) network; as well as Glass Cockpit Avionics.

Last week, Astro Aerospace announced that it acquired the assets to VTOL industry leader, Passenger Drone. Astro Aerospace’s Passenger Drone is a state-of-the-art aerial transport vehicle. It is slated to improve urban mobility and allow passengers to arrive at their destination fast and safe.

The Drone has a sleek design. Moreover, it offers structural efficiency. The Drone’s fiber-optic technology lessens aircraft weight magnetic interference. Astro Aerospace’s functioning prototype includes its VTOL capabilities.

Mr. Bruce Bent, Chief Executive Officer of Astro Aerospace, said, “We’re excited to take Astro’s technology and prototype and bring it to the general public, giving the opportunity to everyone who has dreamed of flying the ability to experience the thrill in a safe and controlled environment with the Astro Passenger Drone.”

Astro Aerospace Ltd. (ASDN), closed Tuesday's trading session at $1.52, up 8.57%, on 52,390 volume with 57 trades. The average volume for the last 60 days is 4,117 and the stock's 52-week low/high is $0.006/$1.40.


Applied Biosciences Corp. (APPB)

Penny Stock Hub, Stockhouse, InvestorsHub, Daily Marijuana Observer, Simply Wall St, TradingView, OTC Markets, Investors Hangout, Stockopedia, and The Stock Market Watch reported on Applied Biosciences Corp. (APPB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets Group’s OTCQB, Applied Biosciences Corp. is a diversified cannabinoid therapeutics company. It centers on the on the medical, bioceutical and pet health industries. The Company was previously known as Stony Hill Corp. Applied Biosciences has its corporate headquarters in Beverly Hills, California.

On April 2, 2018, Applied Biosciences announced that it received notice of approval regarding its earlier announced name change. In addition to the name change, the Financial Industry Regulatory Authority (FINRA) approved 'APPB' as Applied Biosciences’ new ticker symbol.

The Company’s focus is on select investment, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceuticals and media industries. Applied Biosciences products include Remedi CBD and TherPet.

The Company uses organic ingredients and formulations, which were created to target common ailments in the health and wellness industry for anyone who is open to trying hemp derived products. The products use industrial hemp as an input to produce high quality CBD for an array of health and wellness products. Remedi CBD is a line of premium hemp-derived CBD products. These products include topicals, gummies, and more.

Last month, Applied Biosciences announced that it expanded its product line and launched a hemp-derived CBD product line under the above-mentioned Remedi CBD brand. These products will be sold on Remedi's new website ( and in select locations in the United States.

At present, the new e-store offers Applied Biosciences' line of hemp-derived cannabidiol (CBD) isolate infused gummies, topicals, capsules and tinctures. The Company is continuing to launch its product lines in select specialty and retail stores.

In addition, in April, Applied Biosciences announced that it started sales of its hemp-derived CBD products on LeafLink's industry-leading B2B (Business-to-Business) e-commerce platform. LeafLink is the top B2B platform for orders, sales and relationship management for product brands and retailers.

Last week, Applied BioSciences announced that its wholly-owned animal health subsidiary, TherPet, entered the equine health marketplace with the launch of a new full-spectrum hemp-derived cannabidiol (CBD) supplement formulated specifically for a horse's health and wellness.

TherPet's Equine Care CBD line is a natural supplement. The design of it is to play a vital role in keeping horses, healthy, looking good and performing their best. The Company’s Equine Care CBD products support healthy skin, joints and immune system. These products are also for easing the discomfort of fatigued muscles, stiff joints and arthritis pain.

Applied Biosciences Corp. (APPB), closed Tuesday's trading session at $2.05, down 0.49%, on 200 volume with 3 trades. The average volume for the last 60 days is 749 and the stock's 52-week low/high is $1.00/$3.50.


Lot78, Inc. (LOTE)

Promotion Stock Secrets, Street Register, OTC Markets, Emerging Growth, Aim High Profits, Insider Financial, Penny Stock Tweets, Stockwatch, Penny Stock Dream, Hotstocked, and Predict Wall Street reported on Lot78, Inc. (LOTE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Lot78, Inc. designs, markets, distributes and sells apparel under the Lot78 brand name. It operates in three segments: Wholesale, Consumer Direct, and Core Services. Ollie Amhurst is the Founder and Creative Director of the Company. From the start, the business strategy was to build Lot78 into a men’s and women’s ready to wear line. Lot78 has its head office in London, England.

The Company was incorporated in Nevada on June 27, 2008. On March 14, 2011, it filed a Certificate of Amendment with the Secretary of State of Nevada changing the name of the Company to "Bold Energy, Inc."

On November 12, 2012, the Company, then under the name Bold Energy, entered into a Share Exchange Agreement with Anio Limited a limited liability company formed under the laws of the United Kingdom (Anio Ltd.) that conducts its main line of business under the name Lot78, Inc., the shareholders of Anio Ltd., and the controlling stockholders of the Company.

On January 31, 2013, it changed names to Lot78, Inc.  On July 15, 2016, the Company entered into a Letter of Intent (LOI) to merge with Compound Holdings, LLC, a Connecticut limited liability company. Then, on July 18, 2016, the Company and Compound Holdings LLC entered into a definitive Agreement and Plan of Merger. With this plan of merger, upon closing, its intention is to change its name to Compound Holdings, Inc.

Lot78 offers a collection of men's and women's ready to wear line that includes leather jackets, T-shirts, sweats, knitwear, accessories, jeans, chinos, and wool coats. The Company sells its products to department stores, specialty retailers, and boutiques. In addition, it sells its products via

In October of 2017, Lot78 announced that it was scheduled to acquire a 2.5 percent equity stake in Garage Juice Bar, LLC also known as Juice Bar Electric Vehicle Charging Stations. Lot78 stated that this investment aligns with the Company’s mission to provide value to shareholders via the acquisition of investments, which show potential to be scaled regionally and/or nationally or investments that drive outsized returns.

Lot78, Inc. (LOTE), closed Tuesday's trading session at $0.03528, up 0.23%, on 62,283 volume with 5 trades. The average volume for the last 60 days is 61,531 and the stock's 52-week low/high is $0.03/$0.4299.


Empire Diversified Energy, Inc. (MPIR)

YCharts, Investors Hangout, PennyStockHub, EquityNet, OtcDynamics, Penny Stock Tweets, DividendInvestor, MarketWatch, OTC Markets, InvestorsHub, Morningstar, Investing, Stockhouse, Stockopedia, Biz Journals, and Hot Penny Stocks reported on Empire Diversified Energy, Inc. (MPIR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Empire Diversified Energy, Inc.’s principal mission is to serve the challenges of the energy Industry with unique solutions mainly related to the safe removal and disposal of Coal Combustion Residue (CCR), normally referred to as coal ash, from the nation’s utilities storage ponds. In essence, Empire’s corporate mission is to help clean up the existing environment and develop clean fuel sources in the future. Empire Diversified Energy is headquartered in Fort Lauderdale, Florida.

Currently, the Company is initiating coal-reduction strategies involving increased use of sustainable biomass. Additionally, its longer-term plans will be to diversify into zero-emission fuel science and the wide-ranging use of economically-viable hydro-electric, solar, and wind technologies.

Empire Diversified Energy plans to acquire certain assets. These include, but are not limited to, logistical equipment, coal mines, landfills, solar equipment and biomass inventories. This is because it is working to implement a vertical integration strategy.

The Company specializes in Diversified Green Energy projects. Empire is a full-service business. It offers strategic consulting and inventive environmental solutions to address industry issues including the above-mentioned CCR remediation and renewable energy alternatives. Empire has identified a niche market opportunity in the fly ash remediation sector.

Empire Diversified Energy acquired DTE Dickerson, LLC. It completed its acquisition on the DTE Dickerson property in May 2017. Assets in the Dickerson included all coal, coal slurry; coal waste and coal refuse located within the property; a surety bond in the amount of $1,203,500; a slurry disposal area; prep plant; and diverse permits.

Empire Diversified Energy is currently developing a hybrid alternative fuel pellet (HAFP). It is intended to allow utilities and other enterprises that now burn solid and gaseous fuel sources to transition from these traditional sources to HAFP’s.

Empire is also developing its own proprietary binding agent. This binding agent will permit HAFP’s to be utilized across a more broad range of platforms.

HAFP’s are produced, in part, with high-grade reclaimed coal fines, blended with cellulose (wood) and/or other biomass material in an 80/20 configuration. Therefore, the resulting product is a cleaner, renewable fuel source with similar BTU output to pure coal.

Empire Diversified Energy, Inc. (MPIR), closed Tuesday's trading session at $1.40, up 40.00%, on 600 volume with 6 trades. The average volume for the last 60 days is 291 and the stock's 52-week low/high is $0.312/$5.00.


TapImmune, Inc. (TPIV)

Penny Stocks Finder, InvestorSoup, Penny Pick Finders, Stock News Now, SeeThruEquityResearch, Stock Preacher, Beacon Equity Research, SuperStockTips, Penny Stock Craze, and Pennybuster reported earlier on TapImmune, Inc. (TPIV), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

TapImmune, Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies presently continuing for the treatment of ovarian and breast cancer. The Company’s peptide or nucleic acid-based immunotherapeutics consist of one or multiple naturally processed epitopes (NPEs). The design of these is to comprehensively stimulate a patients' killer T-cells, helper T-cells, and to restore or further augment antigen presentation through using proprietary nucleic acid-based expression systems. TapImmune is based in Jacksonville, Florida.

The Company has developed an innovative, cost effective, immunotherapeutic vaccine expression and delivery system. The novel platform is called TapImmune's PolyStart™ technology. The PolyStart and PAA (Peptide Antigen Array) technologies are straight forwardly and easily managed as a fast, adaptable, plugin-and-play system. This means they can be configured to produce peptides for any desired pathogen.

TapImmune’s PolyStart™ technology has been strategically designed to directly enhance the immune system's ability to stimulate either or both cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or any cancer, infectious disease, or bio-threat. The current emphasis of its PolyStart technology is on its cancer program (e.g., Her2/neu and folate receptor alpha antigens).

This past November, TapImmune announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV200 for treating triple-negative breast cancer (TNBC). The design of the wide-ranging four-arm study is to help determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine's molecular target, folate receptor-alpha (FRa). This is a cancer cell biomarker that is highly correlated with disease recurrence.

Moreover, TapImmune started enrolling patients into a Phase 2 platinum-sensitive ovarian cancer study under an amended protocol that allows women in their first remission to receive TPIV200 vaccination. In addition, the Company continued to advance its clinical development pipeline in manifold Phase 2 studies in ovarian and breast cancer.

Last month, TapImmune announced that the first patient was enrolled in a Phase 2 randomized, multi-center, double-blinded, placebo-controlled clinical trial of TapImmune's novel therapeutic vaccine candidate TPIV200. The 280-patient trial, sponsored by Mayo Clinic, received $13.3 million in grant funding from the U.S. Department of Defense (DoD) to evaluate the prevention of cancer recurrence in women with triple-negative breast cancer (TNBC) who have completed first-line surgery and radiotherapy/chemotherapy.

TapImmune, Inc. (TPIV), closed Tuesday's trading session at $3.026, up 0.87%, on 70,342 volume with 220 trades. The average volume for the last 60 days is 41,049 and the stock's 52-week low/high is $2.58/$4.41.


Nutriband, Inc. (NTRB)

Stockopedia, MarketWatch, InvestorsHub, Stockhouse, Market News Updates, Morningstar, Stockwatch, Simply Wall St, GuruFocus, Barchart, InsiderMole, 4-Traders, The Street, OTC Markets, Penny Stock Hub, and Insider Monkey reported on Nutriband, Inc. (NTRB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A Nevada Corporation, Nutriband, Inc. is a health and pharmaceutical Company. The basis of all the Company’s products is around the science of transdermal /Topical technologies. Nutriband has its head office in Orlando, Florida. The Company lists on the OTC Markets Group’s OTCQB.

The design of Nutriband’s products is on the principle that molecular combinations can be absorbed not only orally but also through the skin. Due to the intake method, all of the Company’s products contain nothing but the bare essential ingredients. This is because there is no need for binders, fillers or unwanted animal by-products such as gelatine.

Nutriband Life Sciences is the pharmaceutical division of Nutriband, Inc. Nutriband Life Sciences centers on the development, research and marketing of unique drug delivery systems. At present, Nutriband’s drug pipeline is in formulation, feasibility, and also pre-clinical evaluation.

In April, Nutriband announced the acquisition of 4P Therapeutics, Inc. on April 5, 2018. Nutriband acquired 100 percent interest in 4P Therapeutics for a total of $1,900,000 payable in company stock and cash.  4P Therapeutics will receive 250,000 shares of common stock and a cash amount of $400,000.

4P Therapeutics will become the Pharmaceutical and Development arm of Nutriband. 4P Therapeutics will have a specific emphasis on Transdermal and Topical Technologies, prescription drugs, as well as clinical development.

Included in the acquisition of 4P Therapeutics’ Intellectual Property (IP) Portfolio is Defent™ abuse deterrent patch technology. This is an opioid abuse deterrent platform for the transdermal delivery of opioid-based medications. Defent™ reduces the risk of abuse and misuse, creating a safer treatment for patients.

Last week, Nutriband announced that it signed an exclusive 20-year; $90 million distribution agreement for its transdermal consumer product lines with Best Choice, Inc. Best Choice is a Korean consumer products distributor. Best Choice has a two decade history of working with major chain retailers.

Today, Nutriband announced that it appointed Mr. Jeff Patrick PharmD as Chief Scientific Officer and to the head of its Pharmaceutical Advisory Board.

Jeff Patrick PharmD presently serves as Director of Drug Development Institute at the Ohio State University Comprehensive Cancer Center. Most recently, Dr. Patrick served as Chief Scientific Officer for New Haven Pharmaceuticals. 

Nutriband, Inc. (NTRB), closed Tuesday's trading session at $6.50, up 18.18%, on 325 volume with 4 trades. The average volume for the last 60 days is 647 and the stock's 52-week low/high is $1.55/$6.55.


Naked Brand Group, Inc. (NAKD)

Stock Twits, Zacks, Street Insider, InvestorsHub, Stockhouse, BusinessInsider, Simply Wall St, The Street, Equities, Stockopedia, Investing, Barchart,, and Stock News Journal reported on Naked Brand Group, Inc. (NAKD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Naked Brand Group, Inc. designs, manufactures, and sells men's and women's underwear, intimate apparel, loungewear, and sleepwear products in the U.S. and Canada. The Company founded Naked to create a new standard for how products worn close to the skin fit, feel, and function. An innovative fashion and lifestyle brand, Naked Brand Group is headquartered in New York, New York. The Company lists on the Nasdaq Capital Market.

Naked Brand Group is led by distinguished designer and sleepwear pioneer and Chief Executive Officer, Carole Hochman. She joined the Company in 2014.

The Company’s plan is to expand into more apparel and product categories, which exemplify the mission of the brand. This includes activewear, swimwear, sportswear, and more.

Naked's women's and men's collections are available at, and also through some of the foremost online retailers and department stores in North America. These include Bloomingdale's, Dillard's, Soma, Saks Fifth Avenue,, and, among others.

Naked’s Luxury collection uses Lenzing MicroModal®. This is a very ecological, all-natural, and breathable fabric extracted from European beechwood. The cellulosic properties of Lenzing Modal® fiber naturally inhibit odor-causing bacterial growth.

The Company’s Active collection uses microfiber, and very fine synthetic fiber, weighing less than one denier. It can be woven into textiles with the texture and drape of natural-fiber cloth; this is with enhanced wash ability, breathability, as well as water repellency.

Naked’s Essential collection uses cotton - a natural fiber. Cotton is lightweight, soft and breathable. Moreover, the Company’s Signature collection uses a cotton/modal blend. Through blending two of the best fabrics together, it creates the supple, softness of modal with the light and natural feel of cotton.

The Company’s Hybrid collection uses Tencel. This is a sustainable fabric regenerated from wood cellulose. Tencel is one of the most environmentally friendly regenerated fabrics.

In September 2017, Naked Brand Group, Bendon Limited, an international leader in intimate apparel and swimwear and Naked’s merger partner, and Bendon Group Holdings Limited (Holdco), announced that Holdco confidentially submitted a draft registration statement on Form F-4 with the Securities and Exchange Commission (SEC) related to the earlier announced business combination between the parties.

In November 2017, Naked Brand Group, Bendon Limited, and Bendon Group Holdings Limited (Holdco), announced that Holdco confidentially submitted its response to comments from the SEC concerning the confidentially filed draft registration statement on Form F-4 related to the previously announced business combination between the parties.

Naked Brand Group, Inc. (NAKD), closed Tuesday's trading session at $1.30, up 0.20%, on 37,853 volume with 85 trades. The average volume for the last 60 days is 45,377 and the stock's 52-week low/high is $1.11/$3.00.


Nippon Dragon Resources, Inc. (RCCMF)

OTC Markets Group, InvestorPlace, and Streetwise Reports reported previously on Nippon Dragon Resources, Inc. (RCCMF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Nippon Dragon Resources, Inc. is a hybrid mining & technology company. It has high potential and advanced stage mining assets combined with a unique and exclusive green mining method. The Company is active in the exploration and development of gold resources in the Province of Quebec.

The Company formerly went by the name Rocmec Mining, Inc. It changed its corporate name to Nippon Dragon Resources, Inc. in April 2014. Nippon Dragon Resources has its head office in Brossard, Quebec.

Nippon Dragon Resources has its Thermal Fragmentation mining method. This is a mining method that uses heat to 'spall' high-grade veins, considerably lessening the use of explosives. The method only extracts the mineralized ore with minimal dilution. The extraction process permits thermal fragmentation with an accuracy of 2 cm to quickly extract any type of hard rock up to 110 cm wide.

With this precision, high grade precious and base metal veins can undergo extraction without dilution. The thermal unit can be set up to extract a specific corridor. Thermal Fragmentation could be used as a stand-alone method or as a first-rate complement to any conventional hard rock mining operation.

The Company’s flagship gold property is Rocmec 1. This is a fully permitted project in Quebec. The project includes a 100-meter deep, two-compartment shaft, and an 844 meters’ decline, permitting access to four levels (50, 90, 110 and 130 meters).

Furthermore, Nippon Dragon has its Denain Project. This project covers two contiguous mining properties (Venpar and Vauquelin) totaling 24 mining titles. The Denain Project is roughly 60 km east of Val d'Or, Quebec.

The Company also has its Courville-Maruska exploration property in Courville Township, around 32 kilometers’ northeast of Val-d'Or, Quebec. The property consists of 20 mining claims encompassing an area of approximately 800 hectares. The property is on a gold-bearing quartz vein system.

Recently, Nippon Dragon Resources announced the confirmation of its strategic partnership agreement with Val d’Or Resources (VOR). This partnership agreement will enhance Nippon’s position as an industry leader with its exclusive and patented Thermal Fragmentation technology.

Via the creation of a new entity, Rocmec Gold, Inc., the new partnership is expected to substantially expand Nippon’s reach within Canada and other important markets. In the Joint Venture (JV), Nippon Dragon Resources will contribute certain assets and resources. VOR will contribute 16 million CDN dollars in cash, based on a predetermined schedule. At term, this will permit VOR to acquire a 49 percent interest in the JV.

Last month, Nippon Dragon Resources announced that it finalized negotiations with Metalfer Mining. This is to provide a Thermal Fragmentation equipment Unit that will be installed in their mining operation in Serbia.

The sale purchase agreement includes a Thermal Fragmentation Unit including a lance-burner and accessories. The sale purchase agreement also includes a four week orientation, on-site training and hands-on instruction in the proper use of the Process and adequate servicing of the Unit. Furthermore, the agreement includes monthly Licensing and Royalty fees.

Nippon Dragon Resources, Inc. (RCCMF), closed Tuesday's trading session at $0.03, up 15.38%, on 6,250 volume with 1 trade. The average volume for the last 60 days is 18,283 and the stock's 52-week low/high is $0.022/$0.06.


InnerScope Hearing Technologies, Inc. (INND)

Stockhouse, Stockopedia, InvestorsHub, Front Page Stocks, YCharts, and MarketWatch reported on InnerScope Hearing Technologies, Inc. (INND), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, InnerScope Hearing Technologies, Inc. is a technology driven business with highly scalable B2B (Business-to-Business) and B2C (Business-to-Consumer) solutions. The Company has plans on opening, operating, and expanding a chain of audiological and retail hearing device clinics.

In September of 2017, InnerScope Advertising Agency, Inc. announced its name change to InnerScope Hearing Technologies, Inc. This change was completed and approved by FINRA (Financial Industry Regulatory Authority). The change was effective September 18, 2017. Incorporated in June 2012, InnerScope Hearing Technologies has its corporate headquarters in Roseville, California.

The Company provides a B2B SaaS (Software as a Service) based Patient Management System (PMS) software program. The design of this is to improve operations and communication with patients.

Furthermore, InnerScope offers a Buying Group experience for audiology practices. This enables owners to decrease product costs and increase their margins.

Additionally, InnerScope Hearing Technologies will compete in the DTC (Direct-to-Consumer) markets with its own line of "Hearables," and "Wearables" and leading-edge Apps on the iOS and Android markets. Basically, the Company’s mission is to innovate and deploy products and services on a scalable platform for the 360-plus million people around the Global Suffering from Hearing Impairment to create an Eco-System around the Company.

The Company’s updated business plan is to scale its infrastructure to develop and deploy a revenue eco-system strategy. This includes expanding the revenue model to other major sectors of the worldwide hearing industry.

InnerScope will create seven separate revenue generating divisions. The Company said that each division will generate revenue and be positioned for growth, thus growing the Company’s market penetration.

This past November, InnerScope Hearing Technologies announced a successful launch as part of the website a Direct-To-Consumer (DTC) E-Commerce Store for its Personal Sound Amplification Products (PSAPs) and its Hearable/Wearable hearing products. InnerScope continues to expand infrastructure and growth capabilities within its new E-Commerce platform, starting with the launch of its E-Commerce DTC Store.

In January, the Company announced it entered into a Letter of Intent (LOI) for exclusive global licensing and distribution with Eltima Software GmbH for its FlexiHub Software as it relates to remote programming of hearing aid devices. In addition, this Agreement creates an ongoing technology partnership between the two companies for future advancements, which can be used for the international audiological and hearing aid industry.

Furthermore, in January, InnerScope Hearing Technologies announced the successful launch of as part of its e-commerce Direct-to-Consumer sales funnel strategy. is a website for the Company’s Personal Sound Amplifier Products (PSAPs). is InnerScope’s dedicated Direct-to-Consumer website store that completes the purchase phase for the consumer.


InnerScope Hearing Technologies, Inc. (INND), closed Tuesday's trading session at $0.032, up 18.52%, on 329,582 volume with 8 trades. The average volume for the last 60 days is 24,266 and the stock's 52-week low/high is $0.0159/$1.50.


Zoom Telephonics, Inc. (ZMTP)

Wall Street Mover, OtcWizard, FeedBlitz, Marketbeat, SmallCapVoice, and OTC Picks reported on Zoom Telephonics, Inc. (ZMTP), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Zoom Telephonics, Inc. is a foremost manufacturer of cable modems and other communications products. The Company designs, produces, markets, and supports cable modems and other communications products under the Zoom, Hayes®, and Global Village® brands. Formed in 1977, Zoom Telephonics is based in Boston, Massachusetts.

The Company’s products include cable modems & gateways, dial-up modems, mobile broadband modems and routers, wireless networking products, ADSL gateways, Bluetooth wireless products, wireless keyboards, and ZoomGuard wireless sensors & controls. Products also include asymmetric digital subscriber line modems, wireless local area networking products, Voice Over IP products (VoIP), wired networking equipment, dialers and related telephony products, wireless sensors and controls, phone jacks and AC power adapters, and language-related specifics.

Zoom Telephonics signed an exclusive license agreement with Motorola Mobility LLC in May of 2015. The license agreement is for the Motorola brand in connection with consumer cable modem products. This includes cable modem bridges, cable modem/routers, and cable set-top boxes containing cable modems, for the United States and Canada. This agreement began on January 1, 2016 and runs through December 31, 2020.

Zoom Telephonics announced in September of 2017 the signing of an amendment to its license agreement with Motorola Mobility to include the exclusive global rights for the Motorola brand for consumer-grade cellular modems and gateways, DSL modems and gateways, as well as MoCA (Multimedia over Coax) adapters.

This amendment also grants Zoom Telephonics non-exclusive global rights to use the Motorola brand for consumer-grade cellular home sensors. These are products designed, marketed, and sold for use by consumers for their personal, family, or household use.

This month, Zoom Telephonics reported financial results for its 2018 Q1 ended March 31, 2018. Net Sales rose 62.0 percent to $8.3 million because of the strength of the Company’s Motorola brand products. Gross Margin improved to 39.4 percent from 33.7 percent. Net Income was roughly $359,000 or $0.02 per share, versus a Net Loss of $1.1 million or $0.07 per share.

Mr. Frank Manning, President and Chief Executive Officer of Zoom Telephonics, said, “We were pleased to report dramatic organic growth, fueled primarily by increased sales of our Motorola brand cable modems and gateways products. Zoom is continuing to grow market share as a result of customers choosing our Motorola products based on strong retail sales channels, product quality, favorable customer reviews, and value.

Zoom Telephonics, Inc. (ZMTP), closed Tuesday's trading session at $3.15, even for the day, on 2,000 volume with 5 trades. The average volume for the last 60 days is 12,311 and the stock's 52-week low/high is $1.71/$4.11.


Acura Pharmaceuticals, Inc. (ACUR)

PennyOmega, PennyToBuck, StreetInsider,, SmarTrend Newsletters, Wall Street Resources, PennyStocks24, Penny Stock Rumble, The Street, BestOtc, BUYINS.NET, CRWEFinance, CRWEWallStreet, StockHotTips, and DrStockPick reported earlier on Acura Pharmaceuticals, Inc. (ACUR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company innovating abuse deterrent drugs. It engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITx™, IMPEDE®,  and AVERSION®, Technologies. Acura Pharmaceuticals is headquartered in Palatine, Illinois.

The intention of the Company’s LIMITX™ Technology is to address an oral Excessive Tablet Abuse (ETA) or accidental consumption of multiple tablets, as well as provide a margin of safety during accidental over-ingestion of tablets. Additionally, LIMITX™ is expected to exhibit barriers to abuse by snorting and injection. LTX-04 is Acura’s lead development candidate using its novel LIMITx™ technology.

The IMPEDE® Technology platform is an advanced polymer matrix. It is used in NEXAFED®, Acura Pharmaceuticals’ pseudoephedrine (PSE) tablet product, to limit or disrupt the extraction of PSE from tablets for conversion into the illicit drug methamphetamine.

AVERSION® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features and benefits for orally administered pharmaceutical drug products. The intention of AVERSION® Technology opioid analgesic product candidates is to provide effective relief from pain. This is while discouraging common methods of pharmaceutical product misuse and abuse.

OXAYDO® (oxycodone HCl immediate-release tablets) that incorporate the AVERSION Technology, is Food and Drug Administration (FDA) approved and marketed in the United States by Acura Pharmaceuticals’ partner Egalet Corp. NEXAFED® and NEXAFED® Sinus are pseudoephedrine containing products that use the IMPEDE Technology. They are marketed in the U.S. by Acura’s partner MainPointe Pharmaceuticals.

This month, Acura Pharmaceuticals announced that topline results from clinical study AP-LTX-301 (Study 301) for its LIMITx™ excess oral abuse deterrent drug LTX-03 identified a formulation, which the Company believes optimizes the balance between providing therapeutic blood levels of drug for pain relief at a single tablet dose while holding back the bioavailability of drug when higher buffer levels are ingested.

Acura Pharmaceuticals’ intention is to submit an Investigational New Drug application (IND) for LTX-03 to the FDA in Q1 2018 and advance to clinical development for a New Drug Application (NDA).  Present FDA approved abuse deterrent opioid formulations do not address abuse by swallowing excess numbers of tablets.

Dr. Al Brzeczko, Acura Pharmaceuticals’ Vice President of Technical Affairs, said, “With Study 301 we believe we have identified a per tablet buffer level that demonstrated good pharmacokinetics for both the efficacious and abused dose levels. We are excited to advance LTX-03 to the IND phase and look forward to beginning the NDA development process.”

Acura Pharmaceuticals, Inc. (ACUR), closed Tuesday's trading session at $0.50, up 13.61%, on 10,040 volume with 2 trades. The average volume for the last 60 days is 7,964 and the stock's 52-week low/high is $0.2855/$0.8702.


MariMed, Inc. (MRMD)

Investors Hub, OTC Markets, and DailyMarijuanaObserver reported on MariMed, Inc. (MRMD), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

MariMed, Inc. is an industry leader in the design, development, operation, funding, and optimization of medical cannabis cultivation and production centers and dispensaries. The Company provides turnkey solutions to cannabis cultivators, producers, and dispensaries. It specializes in solutions for securing and operating facilities, manufacturing and processing, dispensary, layouts, and designs, merchandising and sales. OTCQB-listed, MariMed has its corporate office in Newton, Massachusetts.

MariMed is focusing exclusively on serving the fast expanding $7 billion legal cannabis industry. MariMed reported strong revenue growth for 2016 that continued into 2017. The Company more than doubled revenue in 2016 over 2015, increasing from $1.27 million in 2015 to $3.56 million in 2016. Most of the revenue was attributable to subsidiary MariMed Advisors and its cannabis services and products business.

MariMed is on the vanguard of medical research, working to create precision dosed products to treat specific conditions. Its team has developed state-of-the-art and regulatory compliant facilities in numerous states. These facilities are replicable and scalable models of excellence in horticultural principals, cannabis production, product development, as well as dispensary operations.

The Company provides a complete range of consulting services in the medical cannabis industry. It uses a systematic approach, from the permit and application process, to on-time operational readiness. As Cannabis experts, it specializes in supporting the development of high quality state-licensed, medical cannabis dispensaries and cultivation facilities.

MariMed’s services include application assistance, real estate and safe access, build-out and ongoing consultation, business acceleration solutions, and physician and patient outreach. MariMed Advisors, Inc. has a portfolio of high-quality branded products, product development plans, product packaging, and product licensing opportunities.

In November, MariMed announced that it acquired the rights to the intellectual property (IP), formulations, recipes, proprietary equipment, and expertise of Betty’s Eddies from Icky Enterprises LLC.  This acquisition enables MariMed to further expand its inventive, industry-leading Kalm Fusion™ precision dosed medical cannabis-infused product line.

Betty’s Eddies is a line of fruit chews handcrafted and naturally sweetened with the finest all natural ingredients and non-GMO organic fruits and vegetables. MariMed has a licensing agreement where Canuvo, Inc., will manufacture and distribute  MariMed Kalm Fusion™ and Betty’s Eddies™ branded medical cannabis products in Maine.

Recently, MariMed announced the purchase of a 137,500 sq. ft. industrial building on 17 acres at 167 John Vertente Blvd., in the New Bedford, Massachusetts industrial park for a purchase price of $6,895,000. MariMed will develop roughly 70,000 sq. ft. into a full service state of the art medical cannabis cultivation and production facility. This has been leased to ARL Healthcare, Inc. (ARL), a Massachusetts not for profit corporation.

MariMed assisted ARL Healthcare in its successful application to be awarded a Massachusetts Registered Marijuana Dispensary (RMD) License for cultivation, production, and dispensing of medical cannabis. MariMed will assist ARL Healthcare in the development and ongoing management of the cultivation and manufacturing facility. ARL expects to start cultivation in Q1 of 2018.

MariMed, Inc. (MRMD), closed Tuesday's trading session at $1.62, up 13.29%, on 420,314 volume with 413 trades. The average volume for the last 60 days is 84,481 and the stock's 52-week low/high is $0.201/$1.48.


Q BioMed, Inc. (QBIO)

StockPicksNYC, Stock News Now, and SeeThruEquityResearch reported previously on Q BioMed, Inc. (QBIO), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Q BioMed, Inc. is a biomedical acceleration and development company based in New York, New York. Its dedication is to licensing and acquiring biomedical assets across the healthcare spectrum. The Company formerly went by the name ISMO Tech Solutions, Inc. It changed its corporate name to Q BioMed, Inc. in July of 2015. Q BioMed lists on the OTC Markets’ OTCQB.

Q BioMed’s commitment is to provide these target assets the strategic resources, developmental support, and expansion capital they require to ensure they meet their developmental potential, enabling them to provide products to patients in need. The Company’s mission is to license and acquire ground-breaking life sciences assets from academia or small private companies.

Q BioMed is concentrating on clinical stage and innovative products where the technical, regulatory, as well as commercial risks have been decreased or major valuation inflections are pending. The Company has numerous assets across a broad spectrum of healthcare related products, companies, and sectors. These assets will undergo development to provide returns via organic growth or out-licensing, sale, or be spun out into new public companies.

Q BioMed is also developing a unique molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the lessening of IOP (Intraocular Pressure) - one of the chief causes of glaucoma. The platform is innovative and first-in-class. Q BioMed, together with its partner, Mannin Research, Inc, is the only company targeting this mechanism of action.

Q BioMed has commenced production of Strontium-89 Chloride. This is a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain. AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be used in combination with, or to decrease the need for opiate based drugs, and also in combination with cancer therapeutic drugs.

Q BioMed announced earlier this year an exclusive option agreement with Washington University in St. Louis. With the agreement granting the exclusive right to license the technology, the Company will evaluate the feasibility and usability of GDF-15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule now undergoing optimization for the topical treatment of glaucoma.

Recently, Q BioMed and Bio-Nucleonics announced submission of a regulatory filing to the Food and Drug Administration (FDA) for the approval of a new manufacturing facility. Upon approval by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP (Strontium-89) in accordance with cGMP.

Bio-Nucleonics is the licensor of Strontium 89 Chloride. Strontium-89 is a pure beta emitter. It selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from bone lesions.

Q BioMed, Inc. (QBIO), closed Tuesday's trading session at $3.07, down 0.97%, on 42,148 volume with 92 trades. The average volume for the last 60 days is 92,700 and the stock's 52-week low/high is $2.73/$5.90.


The QualityStocks Company Corner


The QualityStocks Daily Newsletter would like to spotlight FANDOM SPORTS Media Corp. (FDMSF).

Fan-focused entertainment company FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) this morning issued a news release applauding the U.S. Supreme Court’s decision to strike down the Professional and Amateur Sports Protection Act of 1992. To view the full press release, visit:

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRA: TQ42) taps into the primal, unfiltered passion of sports fans from around the world by providing an uncensored social media platform delivered through the FANDOM SPORTS mobile app. As an aggregator, curator and instigator of both company-created and user-generated content, the FANDOM SPORTS app is designed to entertain sports enthusiasts with real-time, interactive content on a mobile only app that offers bragging rights and real-life rewards. True sports addicts will appreciate an app that allows fans to pick a fight or create their own FanFights and rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue, as well as establishes consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

Building on the company’s tag line – “Pick a Fight” – the FANDOM SPORTS app provides an always fresh, authentic rush of deeper-than-surface interactive content that resonates with the targeted age demographic of 18-34. Intense sports fans aren’t afraid of stepping up to the plate to engage other users by unleashing their opinions within the app’s structured debate resolution tool coined “FanFights.” Sports-loving fans can explore, gloat, vote, invite friends, create provocative FanFight topics and play to win while inside the FANDOM SPORTS app, which is currently available in the Apple App store and coming to the Google Play store imminently. The company’s self-learning algorithm predicts and collects user preferences while building relevant personalized FanFight channels, bringing the concept of competitive, in-your-face conversation to a whole new level of sports entertainment.

The FANDOM SPORTS app is free to play (F2P) with in-app purchase and subscription capabilities. The gaming aspect of the ecosystem is built on behavioral economics and delivers multiple revenue streams by maximizing average revenue per daily active user (ARPDAU) and user-generated content (UGC), with select placement of high-impact video and moment-based marketing as part of the brand-sponsored FanFights and in-app offers. The global platform enables applications (either FANDOM SPORTS created or 3rd party apps) to be operated in partnership with leading sports themed brands, leagues, and service providing companies within three verticals – live action, eSports, & fantasy – from around the world by supplying “interactive sports entertainment” to fans. The FANDOM SPORTS platform creates a bullet-proof snapshot of the app’s fan base through a Blockchain supported “PlayerCard” in tandem with the “Engagement Score”, which doubles as an invaluable acquisition and retention tool for its business operators. FANDOM SPORTS hosted transactions are placed on the distributed ledger, making them immutable and public to verified users interacting within the business ecosystem. Tracking this digital footprint provides extremely valuable metadata generated by users’ very dynamic behavior and sports passion.

FANDOM SPORTS’ Brand and Sponsorship partners are harnessing the affluent sports fans age 18-34 with integrated marketing content and service experience. The moments-based marketing integration will translate through FanCoin redemption, in exchange for items provided by programs established by FANDOM SPORTS and its clients. These programs are a key part of the business model and covers, as an example, the following partners; Sports Leagues, TelCo’s service offerings, and Content owners (i.e. FANDOM SPORTS provides new paying customers to the owners of pay-per-view platforms).

“Pick A Fight. Talk Trash. Get Rewarded.”

FANDOM SPORTS Media is an entertainment company that aggregates, curates and produces unique fan-focused content.

The FANDOM SPORTS App is the Company’s core product, which is the ultimate destination for unfiltered raw sports talk. The app allows passionate sports fans to unleash their primal sports passions, pick fights and earn rewards.

So download the app and bring your crew. Talking trash is better with friends. The more you invite, the more FanCoins you earn.

You may also visit the Company’s website at or contact them directly at


The CSE has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. This news release may contain forward-looking statements. These forward-looking statements do not guarantee future events or performance and should not be relied upon. Actual outcomes may differ materially due to any number of factors and uncertainties, many of which are beyond the Company’s control. Some of these risks and uncertainties may be described in the Company’s corporate filings (posted at

The Company has no intention or obligation to update or revise any forward-looking statements due to new information or events

FANDOM SPORTS Media Corp. (FDMSF), closed the day's trading session at $0.1029, up 24.13%, on 10,500 volume with 4 trades. The average volume for the last 60 days is 12,701 and the stock's 52-week low/high is $0.0629/$0.3911.

Recent News


Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ).

Epazz, Inc. (OTC: EPAZ), a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions, has announced that the company’s ZenaPay app and blockchain apps will benefit from the recent Supreme Court decision to allow states to legalize sports betting.

Epazz, Inc. (EPAZ) is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company’s strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

“We are starting 2018 with ZenaPay on both major mobile apps’ platforms,” said Shaun Passley, PhD, CEO and founder of Epazz. “We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company.”

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz’s unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

“Blockchain-based technology is the future of the Internet,” Passley said. “Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come.

Epazz, Inc. (EPAZ), closed the day's trading session at $0.0888, up 28.70%, on 331,614 volume with 57 trades. The average volume for the last 60 days is 156,671 and the stock's 52-week low/high is $0.0045/$0.52.

Recent News


Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Global life sciences company Pressure BioSciences (OTCQB: PBIO) today announced financial results for the first quarter ended March 31, 2018. Among other highlights, Pressure BioSciences reported total revenue of $610,774 for the first quarter of 2018 compared to $551,357 for the same period in 2017, demonstrating an increase of 11%.

Pressure BioSciences Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.90, up 19.27%, on 1,100 volume with 4 trades. The average volume for the last 60 days is 1,441 and the stock's 52-week low/high is $0.70/$8.50.

Recent News


Pivot Pharmaceuticals Inc. (PVOTF)

The QualityStocks Daily Newsletter would like to spotlight Pivot Pharmaceuticals Inc. (PVOTF).

Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning provided an update to shareholders regarding the current state of the company. To view the full press release, visit:

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

Pivot Pharmaceuticals Inc. (PVOTF), closed the day's trading session at $0.24, up 4.94%, on 68,495 volume with 35 trades. The average volume for the last 60 days is 88,158 and the stock's 52-week low/high is $0.047/$2.46.

Recent News


SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint, Inc. (OTCQB:SING), on the heels of the Supreme Court overturning a 1992 federal law prohibiting sports betting in 46 states, announces it has invested in an additional betting platform, StakeHaul, the No. 1 social betting app in the iTunes App Store.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.031, up 7.27%, on 11,824,056 volume with 299 trades. The average volume for the last 60 days is 8,123,101 and the stock's 52-week low/high is $0.0132/$0.415.

Recent News


Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Choom™ (CSE: CHOO; OTCQB: CHOOF) is aggressively pursuing retail opportunities in the Canadian marketplace. Choom has secured the rights to an additional 8 retail locations in Alberta, increasing the total to 17 applications in the approval process with the Alberta Gaming and Liquor Commission ("AGLC"). Also today, CHOOF was highlighted in an article on the burgeoning Canadian cannabis industry, which is already comprised of companies worth an estimated $23 billion, is set to explode as the country nears nation-wide legalization of the substance.

Choom Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.7093, up 1.33%, on 213,905 volume with 217 trades. The average volume for the last 60 days is 155,246 and the stock's 52-week low/high is $0.125/$0.8612.

Recent News


Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

MARIJUANA COMPANY OF AMERICA INC. (OTC:MCOA) and joint venture partner Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) are pleased to provide an update on their CBD hemp farming project in Scio, Oregon. Also today, CannabisNewsWire released a report featuring MCOA which details how both companies stand poised to benefit from a booming market for CBD (cannabidiol) from industrial hemp to be grown at the aforementioned farm.

Marijuana Company of America Inc. (MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.03, up 1.69%, on 4,522,602 volume with 237 trades. The average volume for the last 60 days is 5,286,834 and the stock's 52-week low/high is $0.0181/$0.0728.

Recent News


Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF)

The QualityStocks Daily Newsletter would like to spotlight Global Hemp Group, Inc. (GBHPF).

Marijuana Company of America Inc. (OTC:MCOA) and joint venture partner Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) are pleased to provide an update on their CBD hemp farming project in Scio, Oregon. Also today, CannabisNewsWire released a report featuring GBHPF which details how both companies stand poised to benefit from a booming market for CBD (cannabidiol) from industrial hemp to be grown at the aforementioned farm.

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTCQB: GBHPF), headquartered in British Columbia, Canada, is a publicly traded company founded in 2014. Global Hemp Group is focused on acquiring and developing a strategic portfolio of like-minded companies that believe in the significant potential of the industrial hemp plant. Global Hemp Group’s focused on attracting joint venture partners across all sectors of the industrial hemp industries with the commitment to improve quality of life by researching, developing and distributing sustainable materials, products and services produced from hemp.

The company’s mission is to build a strategic portfolio of hemp-based companies that operate synergistically to consistently deliver a solid ROI to its shareholders. Global Hemp Group has established the concept of Hemp Agro-Industrial Zone (HAIZ) ( in order to build cooperative mechanisms across industrial sectors with a focus on different parts of the hemp plant. Under the HAIZ strategy, Global Hemp Group brings together capital, farmers and labor in an effort to build a “soil-to-shelf” portfolio of complimentary companies and joint venture partners in the global hemp industry.

Global Hemp Group has chosen to only work with suppliers of high quality, sustainable raw materials and finished products derived from the hemp plant. Among the leading industries utilizing industrial hemp’s exceptional properties is the automotive sector, building materials market, bio-composites, energy-related markets, super-foods, nutritional supplements, nutraceuticals and the cannabinoid markets. Guided by the principal theme of “global environmental stewardship,” Global Hemp Group focuses on the key concepts of sustainability and social responsibility in all its endeavors.

Global Hemp Group’s joint venture with publicly traded Marijuana Company of America on hemp cultivation trials in 2017, designed to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada, for the first time in 20 years, was a great success. The partners are preparing for the upcoming changes in Canada’s cannabis legislation that will permit cannabinoid extraction from industrial hemp. Farmers have already been recruited to plant a minimum of 125 acres of industrial hemp for the 2018 growing season, with the goal of increasing the acreage under cultivation to 1,000+ acres by year three of the joint project. Global Hemp Group is preparing an application for a processing license to extract cannabidiol (CBD) and other cannabinoids from the upcoming industrial hemp crop. Discussions are also underway with potential processing partners for the extraction of cannabinoids and straw processing for building materials for the upcoming harvest in October 2018, with a longer term plan to establish permanent processing facilities by October 2019.

Global Hemp Group is led by Charles Larsen as its president, CEO and chairman of the board. Larsen’s more than 30 years of experience working in government, public, private and startup companies as an executive manager includes being the founding president of Medical Marijuana, Inc., the first public company in the Cannabis space. Larsen is also a founder and current director of Marijuana Company of America, Inc., and has been actively involved in the cannabis and hemp industry for nearly a decade. Larsen is joined by Curt Huber, who serves as CFO and director. Huber is an independent corporate and financial consultant with more than 25 years of experience in all facets of public companies among many different sectors including mining, oil and gas, and technology.

Also joining the management team as director is Dr. Paul T. Perrault, an agricultural economist trained in cooperative development and in rural development. Perrault’s experience includes years of consulting on rural development projects introducing new crops in several developing countries and strengthening agricultural research organizations, principally in Africa. Jeff Kilpatrick also serves as a director and is currently a program supervisor of Alachua County Department of Court Services in Gainesville, Florida. Kilpatrick, who spent 21 years in the U.S. Coast Guard, is a member of LEAP – Law Enforcement Against Prohibition – and is president elect for the National Association of Pretrial Services Agencies (NAPSA).

Global Hemp Group’s business philosophy is “A healthier future through sustainable business strategies.“

Global Hemp Group, Inc. (GBHPF), closed the day's trading session at $0.102, off by 4.23%, on 287,013 volume with 64 trades. The average volume for the last 60 days is 153,718 and the stock's 52-week low/high is $0.0115/$0.316.

Recent News


Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8)

The QualityStocks Daily Newsletter would like to spotlight Victory Square Technologies Inc. (VSQTF).

As a founder of Silota Research and Development, Inc., Victory Square Technologies Inc. (CSE:VST) (OTC:VSQTF) (FWB:6F6) will, subject to all requisite regulatory approvals, obtain 12.5% of all issued and outstanding shares of the blockchain technology start-up.

Victory Square Technologies Inc. (VSQTF) is a venture builder that creates, funds and empowers entrepreneurs working in the fields of blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources, and other forms of operational support to help them scale internationally.

Victory Square has made multiple early partnerships and investments in the blockchain space. Approximately three years ago the company incubated and invested in BTL Group, which is now a $150 million dollar TSX-listed company offering blockchain solutions across multiple industries with particular focus on the finance, energy and gaming sectors. BTL’s showcase product – Interbit – is a blockchain platform that facilitates the rapid development of business applications that dramatically improve efficiency. Some of the world’s largest institutions are using Interbit to explore new opportunities on private blockchains.

A new social sports betting platform to be developed by Victory Square’s wholly owned subsidiary, FansUnite Media Inc. As a social sports data platform, FansUnite relies on robust data to allow members of its community to engage with like-minded individuals by collaborating, discussing, and predicting the winners of sporting events with a free virtual currency. The integration of blockchain technology into FansUnite’s social sports data platform could also lead to blockchain initiatives developed by other divisions and subsidiaries of Victory Square.

Integral to the FansUnite platform is the introduction of FAN Tokens, an in-game currency purchased with the cryptocurrency Ethereum that token holders can use to place wagers. FansUnite members will be able to earn FAN Tokens through participation in any number of networking effects identified in the company’s Bounty program.

“Blockchain technology and the inherent security it provides will enable us to push every envelope we can to build the most dynamic and responsive social sports betting platform,” said Darius Eghdami, Co-Founder and Chief Executive Officer of FansUnite. “The opportunity to secure data through Blockchain certainly appeals to the accountant in me and we are confident it will become the gold standard among sports betting sites around the world.”

Company subsidiary Victory Square Health Inc., which serves as the venture arm dedicated to companies focused on the development of solutions in personalized health technologies, has also invested in Personalized Biomarkers Inc. (PBI). PBI develops test kits that reliably predict the expected response to a number of therapies prior to prescription, with an initial focus on diabetes. Within this field, five potential biomarkers have been identified, allowing PBI to enter a $4 billion market opportunity.

“We are excited for the opportunity to partner with Personalized Biomarkers as they have correctly identified a massive market opportunity, and have formed an exceptional team of industry leaders,” said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. “This is another investment that is fully aligned with our newly created subsidiary, and one we expect to significantly impact the landscape of personalized medicine.”

A partnership with Insight Diagnostics Inc., also through Victory Square Health, will focus on the development of a personalized diagnostic solution for the improved management and prevention of Type II diabetes.

The company’s investment in V2 Games, a development and publishing studio of high-quality mobile games, is another example of incubating great ideas. V2 Games is well known for its successful launch of PAC-MAN Bounce and Beast Brawlers, two of the company’s releases that are capturing the gaming world by the millions of downloads.

In a move designed to strengthen its presence in film and entertainment, Victory Square has acquired a 40 percent equity stake in United Film Fund II, LLC, which is producing three major motion pictures in 2017 and 2018 including “What They Had,” starring two-time Academy Award winner Hilary Swank.

“This kind of investment in entertainment and film represents a major plank for our Company going forward and we consider ourselves fortunate to have the opportunity to acquire this 40% stake in the Film Fund,” said Tejani, who has launched more than 40 startups in 21 countries that employ hundreds of people and generate more than $100 million in annual revenues. “We believe it’s another strong initiative in film production for us and our stakeholders,” he added.

Victory Square has strategically positioned itself in the legal cannabis industry through an investment in Tantalus Labs, a Canadian-based cannabis cultivation company. Tantalus Labs optimizes plant health and sustainable cultivation by using a unique, environmentally controlled greenhouse engineered specifically for growing cannabis. Called a “SunLab,” the greenhouse takes 90 percent less electricity, uses filtered rainwater, and cools the growing environment to prevent stagnant moisture, recycling the air every 7 minutes to achieve maximum airflow.

Victory Square and its leadership team have seamlessly transitioned from its former identity as Fantasy 6 Sports Inc, a company focused solely on fantasy sports, mobile gaming and immersive sports, to a strategic technology company that creates, funds and successfully executes leading-edge ideas. A long-time technology entrepreneur and advocate of the industry, Tejani received the Person-of-the-Year Award at the 2017 Technology Impact Awards in British Columbia, a hallmark award category that recognizes betterment of the tech industry through leadership and philanthropic or enterprise skills and talents. Tejani has pledged to match up to $1 million in donated funds to be shared by a number of Canadian endeavors aimed at education and child-safe projects.

“These are exciting and important steps in the evolution and growth of our Company, and which properly and fully align with our strategic plan focusing on our core competencies in Blockchain Technology, Artificial Intelligence, Gaming, Personalized Health, Film and Virtual, Augmented and Mixed Reality,” said Tejani. “We’re spurred on by the success we have had in building on our original forays into fantasy sports, mobile gaming and immersive sports. In addition, we are energized by our most recent initiatives in sports, personalized health and entertainment and the confidence being shown by our shareholders in the dynamic direction of the Company.”

Victory Square Technologies and its management team believe innovation, incubation of excellent ideas and social responsibility are at the core of its growing success.

Victory Square Technologies Inc. (VSQTF), closed the day's trading session at $1.1051, up 4.69%, on 14,418 volume with 20 trades. The average volume for the last 60 days is 36,941 and the stock's 52-week low/high is $0.298/$3.32.

Recent News


The Green Organic Dutchman (TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) is pleased to announce  that, effective April 20, 2018, the Company has been granted a supplemental license from Health Canada for the production of cannabis oils.

The Green Organic Dutchman (TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at

The Green Organic Dutchman (TGODF), closed the day's trading session at $3.00, up 0.13%, 156,746 volume with 332 trades. The average volume for the last 60 days is 11,559 and the stock's 52-week low/high is $2.784/$3.525.

Recent News


Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (STLHF).

Standard Lithium Ltd. (TSX-V:SLL) (FRA:S5L) (OTCQX:STLHF) is pleased to announce that it has entered into a license, exploration and option agreement (the “Option Agreement”) to formalize the memorandum of understanding announced by the Company on October 30, 2017.

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) is a Canadian-based energy exploration and development company that is building one of the largest portfolios of high quality, domestic U.S. lithium brine assets. Its data and technology driven project development model is grounded in knowledge, opportunity and speed. Standard Lithium is led by an innovative and results-oriented management team with a strong focus on technical skills. The company has acquired several prospective lithium brine projects with known geological values consistent with producing basins, including its primary focus, the Bristol Dry Lake, California brownfield project that is permitted for related mineral production with accompanying world class infrastructure which are expected to contribute to faster, lower cost exploration and commercial development programs.

Recent results from a geophysical survey of the 25,000-acre Bristol Lake site suggest a high concentration of lithium-bearing brines are present throughout the company’s mineral lease agreement claims. Standard Lithium’s strategic partner in the venture, National Chloride Corporation of America, is well established in the region. All necessary infrastructure is on site, which gives Standard Lithium immediate access to conduct exploration brine sampling, lithium extraction, evaporation and processing activities, all within a fast-track project development schedule.

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020, at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Standard Lithium’s determination to provide battery-grade lithium materials is bolstered by its recently appointed Scientific Advisory Council. These leading lithium extraction scientists and process engineers will oversee and direct the necessary lithium extraction process testing work. In addition to the Bristol Lake Brine Project, the company signed a Memorandum of Understanding in August with an unnamed New York Stock Exchange-listed company on an option for Standard to acquire lithium exploration and productions rights on 30,000 net brine acres overlying the Smackover formation in a region with a history of commercial-scale brine processing. Management believes lithium-bearing brines are likely present in this area. Smackover brines are metal-rich brine anomalies in reservoir rocks along the Gulf Coast from east Texas to Florida known to be a prime lithium resource. This resource may be one of the most promising ones to develop, given that a large-scale brine extraction, processing and reinjection industry is already well established.

Recently, Standard Lithium closed a multi-million dollar private placement offering, which allows the company to advance its current projects and pursue strategic acquisitions in the lithium sector. The company is well positioned with significant exploration opportunities featuring low cost production costs, easy transport, proximity to demand, and access to innovative production methodology.”

Standard Lithium Ltd. (STLHF), closed the day's trading session at $1.168, off by 2.67%, on 1,000 volume with 1 trade. The average volume for the last 60 days is 29,353 and the stock's 52-week low/high is $0.6978/$2.23.

Recent News


Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P)

The QualityStocks Daily Newsletter would like to spotlight Liberty Leaf Holdings Ltd. (LIBFF).

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P), a vertically integrated cannabis company with strategic investments, continues its push to be ready for the green rush coming to Canada’s cannabis consumers. According to Statista, the medical marijuana market in Canada is projected to be worth C$1.1 billion in 2020 (

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) is a publicly traded Canadian-based company with strategic investments in businesses that are established, revenue- producing players in the medicinal and recreational cannabis market. Liberty Leaf’s focus is to build and support a diversified portfolio of cannabis-sector businesses, including those involved in the cultivation and processing of legal medicinal and recreational cannabis, value-added CBD/THC pet products, and supply-chain products for this dynamic and fast-growing sector. Liberty Leaf provides funding, management, HR resources and marketing expertise to help companies thrive and accelerate growth.

Liberty Leaf’s leading investments to date include:

  • North Road Ventures – An emerging end-to-end distributor of cultivated and manufactured cannabis products to licensed legal retailers. North Road has updated its application for an Access to Cannabis for Medical Purposes Regulations (ACMPR) license to be distribution/sales-focused, making the company unique in the crowded field of other cultivation-based applicants. This forward-thinking initiative will help fulfill the anticipated increase in Canada’s recreational cannabis space once legalization takes effect in mid-2018. The submission includes a boost in product-vault capacity that will result in a five-fold increase in products available for distribution. Cannabidiol (CBD)-oil products are expected to account for 50 percent or more of projected sales.
  • Just Kush Enterprises – Liberty Leaf holds a 60 percent interest in Just Kush, a cultivator of premium, proprietary cannabis strains selected for different levels of CBDs and THCs. Just Kush’s cultivation facility is located near Oliver, British Columbia, and it currently controls a facility which holds a Medical Marihuana Access Regulations (MMAR) license. The company is also a late-stage applicant for an ACMPR license (Access to Cannabis for Medical Purposes Regulations), which will enable Just Kush to produce cannabis for the medicinal and recreational market.

Liberty Leaf is also an active partner with the following companies:

  • ESEV R&D – A privately owned, medical marijuana research and development company based in New York with clinical laboratories located in Israel. ESEV R&D, in collaboration with a leading clinical research organization in Israel, has launched a one-of-a-kind service for North American medical cannabis companies to organize and oversee clinical trials seeking to demonstrate the efficacy of medical cannabis products for specific medical conditions. Liberty Leaf has a three-year collaborative agreement with ESEV. Under that agreement, ESEV is researching the efficacy of CBDs in pets, with the 1st formulation trial targeting canine osteoarthritis, a medical condition that includes: hip dysplasia; elbow dysplasia; and hind-knee, also known as stifle, degenerative joint disease (DJD).
  • Blox Labs Inc. – A boutique technology development company focused on creating best-in-class software solutions driven by emerging trends in blockchain, smart contracts and decentralized application technologies. Liberty Leaf and Blox Labs are developing “cannaBLOX,” a blockchain-based smart contract supply chain management platform for the legalized cannabis industry. The cannaBLOX blockchain software will aim to ease and obliterate logistical bottlenecks, ensure product safety and quality of supply, minimize fraud and potential criminal activity, and assist with taxation and regulatory compliance across various levels of government within the legalized cannabis marketplace. To date, preliminary framework and analysis required for a cannaBLOX Whitepaper has been completed and a development team that specializes in blockchain and decentralized application technologies, including omni-language development in Ethereum and NEO, is now working on the project.

The company’s management team is led by President and Director William Rascan who has 25-plus years in the investment brokerage industry, most recently as a partner, senior investment advisor with Northern Securities. Rascan’s business experience ranges from active international trading clients to raising capital for junior mining companies on the TSX Venture Exchange.

Rascan is joined by CFO Jamie Robinson, a chartered accountant who specializes in accounting, auditing, and financial reporting under both IFRS and ASPE. Prior to joining Liberty Leaf, Robinson worked at Deloitte as a manager focused on publicly listed and private company audits, business review, performance enhancement engagements and restructuring proceedings.

Steven Feldman, who has more than 25 years of experience in the capital markets and was part of the original management team of SouthGobi Resources; and Doug Macdonell, a retired RCMP officer and recognized expert in the field of cannabis and cultivation, serve as company directors. Dr. Robert Jackman, who has worked closely with multiple clients in the medical cannabis and Natural and Non-prescription Health Products (NNHP) industries in North America, was recently appointed as scientific project manager/fulfillment.

Liberty Leaf’s advisory board includes international lawyer, writer and speaker Robert W.E. Laurie; Barinder Rasode, who currently serves as CEO of the National Institute for Cannabis Health & Education (NICHE); and Dr. Mary C. Fitzpatrick, B.S., D.V.M., whose primary focus is on helping companion animals live pain free in their senior years.

Liberty Leaf Holdings Ltd. (LIBFF), closed the day's trading session at $0.2499, off by 3.88%, on 11,185 volume with 20 trades. The average volume for the last 60 days is 55,726 and the stock's 52-week low/high is $0.0091/$0.8074.

Recent News


Hiku Brands Co. Ltd. (DJACF)

The QualityStocks Daily Newsletter would like to spotlight Hiku Brands Co. Ltd. (DJACF).

The Canadian cannabis industry, already comprised of companies worth an estimated $23 billion, is set to explode as the country nears nation-wide legalization of the substance. This has resulted in an increase in mergers and acquisitions in the space, as well as overall high activity on the stock markets in the cannabis sector targeting entities such as Hiku Brands Company Ltd. (CSE:HIKU) (OTC:DJACF).

Headquartered in British Columbia’s picturesque Okanagan Valley, Hiku Brands Co. Ltd. (CSE: HIKU) (OTC: DJACF) iis a premium cannabis lifestyle brand growing high-quality handcrafted cannabis flower. Hiku’s wholly owned subsidiary is a licensed producer of cannabis under the ACMPR that has requested its Pre-Sales License Inspection, the last step prior to receiving a license to sell cannabis under the ACMPR. Hiku’s Dominion Facility is a state-of-the-art ACMPR licensed production facility capable of producing approximately 660 kg year of dried cannabis flower. Hiku’s second facility, a 22,580 sq ft warehouse, “the FUTURE LAB”, is targeting its Phase 1 completion by Q2 2018 and once the facility is fully built-out utilizing an industry leading multi-tier system powered by LED lighting provided by Fluence BioEngineering, Hiku’s annual production capacity is expected to be in excess of 5,000 kgs. Hiku was founded by the proven entrepreneurial team that started SAXX Underwear®.

On December 21, 2017, Hiku and TS Brandco Holdings Inc. (“Tokyo Smoke”) announced that they have entered into a binding Letter of Intent (“LOI”) to merger the two companies and create a uniquely positioned cannabis company combining a best-in-class craft cannabis producer with an award-winning lifestyle brand and retail-focused cannabis company. It is anticipated that the combined company resulting from the merger will use the name “Hiku Brands Company Ltd.” (“Hiku”) to refer to the brand house containing premium cannabis brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku recently closed on a $10 million strategic equity investment from Aphria Inc. (“Aphria”) (TSX:APH and US OTC: APHQF) to expand their product offering ahead of the recreational market.

Upon completion of the merger, Hiku will have a robust cash position of approximately $31 million, which it plans to invest in expanding its cannabis production capacity, growing its retail footprint, and adding select brands to its portfolio through highly strategic and complementary acquisitions.

About Tokyo Smoke
Founded in 2015 by Alan and Lorne Gertner, Tokyo Smoke is an award-winning cannabis lifestyle brand that brings sophistication and design to the fast-growing industry. With immersive experiences and design-first, non-dispensary retail spaces selling coffee, cannabis accessories and design products, the brand has six locations in Canada, with plans to expand nationwide. Recently named “Brand of the Year” at the Canadian Cannabis Awards, Tokyo Smoke has showcased excellence in brand storytelling, and has developed an international reputation as the go-to destination for engaging content offerings within the industry. With the acquisition of fellow designer cannabis brand Van der Pop, and by partnering with Aphria Inc. (TSX: APH and US OTC: APHQF) and WeedMD (TSXV: WMD), Tokyo Smoke continues to be the leading Canadian brand in the cannabis space.

About Hiku
Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku’s wholly owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Hiku Brands Co. Ltd. (DJACF), closed the day's trading session at $1.12, off by 5.08%, on 108,179 volume with 148 trades. The average volume for the last 60 days is 123,414 and the stock's 52-week low/high is $0.20/$3.8799.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.